Monitor F351 NDA decision in China and progress of ETUARY Phase 3 readouts. Evaluate dilution from all-stock deal and integration of Cullgen's platform. Watch for near-term volatility as market assesses combined pipeline value.
Price Chart
Executive Summary
Gyre Therapeutics closed its all-stock acquisition of Cullgen Inc. for approximately $300 million, gaining a commercial-stage lung fibrosis treatment (ETUARY) in China and a pipeline of targeted protein degraders. The combined entity is now led by former Cullgen CEO Dr. Ying Luo. The deal strengthens Gyre's pipeline but introduces integration and execution risks.
Key Financial Metrics
Key Facts
- All-stock acquisition of Cullgen valued at ~$300 million closed.
- Dr. Ying Luo appointed President, CEO, and board member; Ping Zhang remains Chairman.
- Combined entity has commercial product ETUARY (pirfenidone) in China for IPF and a pipeline including F351 for liver fibrosis.
- Cullgen adds targeted protein degrader (TPD) and degrader-antibody conjugate (DAC) platform.
- F351 NDA received priority review in China; Phase 3 trials ongoing for ETUARY in pneumoconiosis and radiation-induced lung injury.
Financial Impact
All-stock transaction valued at ~$300 million; no cash consideration.
Risk Factors
- Integration risk combining two organizations across U.S. and China.
- Clinical and regulatory risks for F351, ETUARY expansion, and early-stage degraders.
- Dilution from all-stock issuance; potential need for additional financing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3286729 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 8-K | $5.85 | awaiting T+20 | — | $6.53 (+11.62%) |
Sep 1, 2026 8w ago | 8-K | $6.47 $7.35 | ▲ +13.52% | ▲ +12.34% | $6.53 (+0.93%) |
Aug 26, 2026 8w ago | 8-K | $6.65 $7.43 | ▲ +11.73% | ▲ +10.53% | $6.53 (−1.80%) |
Aug 7, 2026 11w ago | 8-K | $6.67 $6.86 | ▼ −2.85% | ▼ −3.25% | $6.53 (+2.10%) |
Aug 4, 2026 12w ago | EFFECT | $6.15 $6.47 | ▲ +5.20% | ▲ +6.44% | $6.53 (+6.18%) |
Jul 13, 2026 15w ago | S-3/A | $6.34 $6.64 | ▲ +4.73% | ▲ +2.24% | $6.53 (+3.00%) |
Jun 2, 2026 21w ago | 8-K | $5.56 $6.52 | ▲ +17.27% | ▲ +18.83% | $6.53 (+17.45%) |
May 14, 2026 23w ago | 8-K | $6.55 $5.86 | ▼ −10.53% | ▼ −12.65% | $6.53 (−0.31%) |
May 4, 2026 25w ago | 8-K / DEFA14A | $7.92 $5.81 | ▼ −26.64% | ▼ −32.29% | $6.53 (−17.55%) |
May 4, 2026 25w ago | Press Release | $7.92 $5.81 | ▼ −26.64% | ▼ −32.29% | $6.53 (−17.55%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers